Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 159 participants.
Also called NCT02919059
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 159 participants
- Sponsor
- IInstituto Gallego de Medicina Vascular
- Registry
-
NCT02919059
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Spain
- Registry status
- Unknown status
Technical summary
Registry record NCT02919059. Randomized; double masking; primary purpose treatment. Start 2016-12-13 (actual); primary completion 2018-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Dapagliflozin 10 mg
- Intervention (Drug)
- Glimepiride 4 mg
- Lead sponsor
- IInstituto Gallego de Medicina Vascular
Record details
- Record id
cardio:ct-nct02919059- Content hash
d954ac699a58c3afab96b736a6b6047e8a3de975b9226126eb9cccf4750d5cef